Med-ePHV Project Keeping an Eye on Medicine

Medicines impact the lives of millions of people and strengthen their well-being, but there are risks involved in their use. Scientists agree that risk assessment during drug development should be carried out rigorously, but identifying safety concerns during clinical trials is complex. Pharmacovigilance is a field of science dedicated to the understanding and prevention of the adverse effects of medicines. The Med-ePHV (Learning and practicing pharmacovigilance in the Mediterranean countries) project, funded under the EU's Sixth Framework Programme (FP6) with EUR 804,420, has proposed an innovative approach to EU pharmacovigilance practice.

Health practitioners and patients are the first to recognise Adverse Drug Reactions (ADR) and to notify the appropriate authorities. But the process is complicated by inefficient delivery of notifications to both national and European agencies.

EU pharmaceutical regulators stress the importance of pharmacovigilance to the well-being of European citizens. Med-ePHV sought to design and implement a cooperative e-learning system that addresses the needs and profiles of Mediterranean-based health practitioners and patients, in particular those from Spain, France and Italy.

The project partners believed their innovative system 'would allow the parties involved to learn and practise ADRs notification at the peripheral edge of the pharmacovigilance systems'.

The team also aimed to develop pharmacovigilance e-learning courses and tutoring strategies that comply with EU legislation and can be adapted to the needs of national implementation schemes. They targeted the testing and validation of the e-learning modules in a representative sample of health practitioners and selected pharmaceutical industry representatives.

Finally, the researchers sought to design a cooperative environment as the central component of an 'application grid' that would be accessible to local health authorities and health practitioners. Partnership agreements would then be forged so that the e-learning modules could be commercially exploited.

Launched in September 2006, the grid-based computing platform included an online pilot for training on ADRs notification and reporting that complied with established international standards, and 'pharmacovigilance e-learning courses and tutoring schemes' that both supported knowledge-based ADRs specification and addressed correlation and standardisation issues.

Participating in the project were the small- and medium-sized enterprises (SMEs) Arisoft Editorial (Spain), PasteurMediavita (France) and Gruppo S LAB (Italy). The Spanish group specialises in internet portals targeting the promotion of specialised training programmes in various sectors such as health. PasteurMediavita offers specialised, health-related conventional and internet support training, and Gruppo supplies medical information products.

The SMEs worked together with research and technology development groups, including France's National Institute of Health and Medical Research and the University of Pavia in Italy, to make the project a success. The European Forum of Clinical Good Practice also took part by raising awareness of the project's results at the EU level.

For futher information, please visit:
http://www.medephv.net

Copyright ©European Communities, 2009
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Sanofi and GSK's next-generation COVID-19 booster …

After the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn® Beta, the vaccine was approved by t...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

GSK announces positive Phase IIa study results for…

GSK plc (LSE/NYSE: GSK) announced positive results from a Phase IIa study demonstrating that GSK3036656, a first-in-class investigational antitubercular agent, was well t...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...

Machine learning can help predict patient response…

Predicting which patients will respond well to treatment is a quandary that has plagued the field of cancer immunotherapy for more than four decades. Now, researchers at ...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...